 |
上海源葉生物科技有限公司
主營(yíng)產(chǎn)品： S30260異硫氰酸胍,30259鹽酸胍,嗜熱菌蛋白酶 |
會(huì)員.png)
15
聯(lián)系電話
15921386130
公司信息
- 聯(lián)系人：
- 何小姐
- 電話：
- 86-021-61559134
- 手機(jī)：
- 15921386130
- 傳真：
- 86-021-55068248
- 地址：
- 上海市松江區(qū)長(zhǎng)塔路465號(hào)6幢
- 郵編：
- 200433
- 網(wǎng)址：
- www.shyuanye.com
S80050
| 參考價(jià) | 面議 |
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 型號(hào)
- 品牌
- 廠商性質(zhì) 生產(chǎn)商
- 所在地
更新時(shí)間：2025-05-15 19:37:39瀏覽次數(shù)：136
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息，謝謝!
- 提示：詳情請(qǐng)下載說明書。
- 產(chǎn)品描述： Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87 μM and 0.51 μM for BD1 and BD2, respectively
- 靶點(diǎn)： IC50: 510±41 nM (BD2), 87±10 μM (BD1)
- 體內(nèi)研究： In the atherosclerosis prophylactic treatment study design, mice are fed a Western diet concurrent with the treatment with 150 mg/kg/dose b.i.d. for 12 weeks. Mice are sacrificed at 12 weeks after treatment. There is a progressive increase in body weight in both the vehicle treated as well as the Apabetalone (RVX-208) treated groups. However, there is only an increase of 4 g (from 24 g to 28 g) body weight after 12 weeks on Western diet in the Apabetalone treated group whereas this increase is found to be 9 g (25 g-34 g) in the vehicle treated group. The significant decrease in body weight gain in Apabetalone treated mice is not due to decreased feed consumption, suggesting a positive attribute of the molecule. Plasma lipid measurements are done at 6 weeks and 12 weeks of treatment with either the vehicle or Apabetalone. Compared to the vehicle control animals, Apabetalone treated mice show significant increase (~200%) in the levels of HDL-C at 6 weeks of treatment, which is sustained until end of the study (12 weeks)
- 參考文獻(xiàn)：
1. Picaud S, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9. 2. McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013 Dec 31;8(12):e83190. 3. Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014 Sep;236(1):91-100.
- 溶解度： DMSO : ≥ 33 mg/mL (89.09 mM)
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 2.7 ml 13.499 ml 26.998 ml 5 mM 0.54 ml 2.7 ml 5.4 ml 10 mM 0.27 ml 1.35 ml 2.7 ml 50 mM 0.054 ml 0.27 ml 0.54 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性，僅供客戶參考交流研究之用。
